Global Keloid Treatment Market Overview
The keloid treatment market is expected to reach USD 1.72 Billion by 2032 and is expected to increase at a CAGR of 3.3% during the forecast period 2023-2032. A keloid is a thickened scar that rises over the surrounding skin. It is usually pink or purple. Keloids are unevenly shaped scars that appear on the skin and grow in size over time.
The market for keloid treatment is expected to grow as a result of major innovations in skincare products' technology. As more people learn about the many options for curing keloids, the industry expands to accommodate them. The Keloid Treatment Market has expanded due to a number of factors, including the rising demand for skincare goods and services and the shift toward more health-conscious lifestyles. However, the business is being driven by patients' growing consciousness of their appearance, especially among women. As more people seek help for keloids, medical facilities are increasingly looking to cutting-edge therapy options.
In addition to technological progress and rising knowledge of the availability of aesthetic surgery, an increase in the frequency of road accidents and burn cases has been a major factor promoting the industry's adoption throughout the years. The rising rate of both car accidents and burns around the world is expected to fuel growth in the keloid treatment industry. It is anticipated that technical development will further increase the company's profit margin. Laser therapies are becoming increasingly popular for the treatment and removal of scars. In addition, numerous businesses have recently unveiled cutting-edge laser therapy scar solutions.
In January 2023, Sonoma Pharmaceuticals, Inc., a global leader in the development and production of stabilized hypochlorous acid (HOCl) products for a variety of applications, including dermatology, eye, oral, and nasal care, and wound care, announced the launch of a line of office dispense products designed specifically for skin care professionals. The medications are in prescription strength and include Regenacyn® Plus, Reliefacyn® Plus, and Rejuvacyn® Plus. Regenacyn Plus has been shown in clinical trials to reduce itching and pain associated with keloid and hypertrophic scars, as well as enhance the appearance, texture, and color of the scars itself.
Aesthetic professionals and patients can visualize injectable treatment results when planning through the use of FACE by Galderma™, a new aesthetic visualization tool based on augmented reality (AR), launched today by Galderma in March 2023. This will allow a patient to envision whether or not they want to go ahead with an injection. An individualized treatment plan might offer simulated real-time before and after photos, which would help allay anxiety about injectables. Thus, through FACE by Galderma, there can be an immersive interactive consultation between the provider and the patient. It is designed for aesthetic practitioners and evaluates skin quality, face shape, proportion, contouring symmetry, and facial expressions expressed through animations.
In February 2022, Merz Aesthetics announced its commercial release of Radiesse® (+) Lidocaine soft tissue filler for deep injection under the skin (subdermal) or above the periosteum (supraperiosteal) in adult patients aged over twenty-one years to correct moderate-to-severe loss of jawline volume. Radiesse Injectables constitute the very first and only calcium hydroxylapatite (CaHA) portfolio in America, whereas Radiesse (+) is currently the single FDA-approved injectable treatment for improving jawline contours. In September 2021, the Food and Drug Administration approved an additional Premarket Approval Application.
Sonoma Pharmaceuticals has just released a line of office dispense products that are exclusively available to skincare specialists; this was made known on January 2023 by Sonoma Pharmaceuticals, Inc., a global healthcare leader that uses patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for various applications such as dermatology, eye care, oral care/healthcare nasal care, wound care among others. The prescription-strength formulations include Regenacyn® Plus, Reliefacyn ®Plus, and Rejuvacyn® Plus. Dermatology practices and medical spas will be the target for Sonoma’s distribution program in-office. Consequently, instead of going to a pharmacy, clients can buy prescription strength products directly from their skin care professional.
The keloid treatment market is segmented into product type, treatment, and end-users.
Based on product type the market is segmented into elastic wraps, spray, ointment, creams, oils, topical gels & gel sheets.
Based on treatment market for keloid has been segmented into ligature, radiation therapy, cry therapy, surgical treatment, laser treatment, steroid injections, corticosteroid injections (intralesional steroids), silicone gel or sheeting, occlusive dressing, compression therapy, and interferon. Corticosteroid injections treatment segments lead the keloid treatment market as this treatment is used in combination with other therapies. Intralesional steroids injection is considered to be the second largest segment of treatment type that drives market.
On the basis of end-users, the keloid treatment market is segmented into dermatology clinics, hospitals, ambulatory surgical centers. Hospital is expected to hold the largest share in the segment market of end-users as most doctors prefer radiation therapy which has reported safe and effective use of radiation to treat keloid.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European keloid treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
In January 2023, The results of a new in-depth examination of data from the UK Biobank into the impact of co-morbidities on disfigurement from keloid and hypertrophic scars (excessive scarring) indicate the need for more research into the pathophysiology of excessive scarring. Atopic eczema in particular was linked to an increased risk of scarring. Keloid scars and hypertrophic scars both result from skin wounds, however keloid scars are permanent whereas hypertrophic scars may fade with time. Candidate disorders based on hypothesized biological or demographic similarities have been the focus of prior research into the co-occurrence of keloids and hypertrophic scars.
Regional Market Summary
Geographically, North America dominates the keloid treatment market and is expected to continue to dominate the market throughout the forecast period. Clinics in North America are adopting advanced technologies for the treatment of keloid. Development of new technologies, product, alternative treatment and high disposable income of people in this region is responsible for the rapid growth of the keloid treatment market in this region.
Europe is the second largest market in the globe owing to the increasing awareness among people, favorable reimbursement scenario for skin treatment, increasing government expenditure for skin care product, the presence of disposable income and increasing demand for the cosmetic product.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of skin caries, increased focus on appearance and aesthetic in the developing countries, rising population, increasing disposable income, and growing healthcare expenditure are anticipated to increase the keloid treatment market in Asia-Pacific.
The Middle East & Africa is expected to account for the lowest market share in the keloid treatment market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.
Global Keloid Treatment Market Share (%), by Region, 2017 
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American College of Prosthodontists
Key players:
Some of the key players in the keloid treatment market are
Keloid Treatment End User Outlook
Recent Development
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â USD 1.72 Billion |
| Â Â CAGR | Â Â 3.3% |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Million) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â By Product, Treatment, End-User |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Novartis AG, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation, Avita Medical Limited, Sensus Healthcare, Perrigo Company plc. |
| Â Â Key Market Opportunities | Â Â Increasing research & development investments by industry players |
|   Key Market Drivers | · Rapid rise in the technological scenario behind skin care products · Treatment type - Intralesional steroids injection |
Keloid Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The global keloid market is expected to reach a valuation of USD 1.72 billion by 2032.
The market is expected to exhibit a strong 3.3% CAGR over the forecast period from 2023-2032.
The rapid rise in the technological scenario behind skin care products is the major driver for the global keloid treatment market.
North America is the dominant regional market for keloid treatment.
Leading players in the keloid treatment market include Valeant, RXi Pharmaceuticals, Novartis, and Pacific World Corporation, among others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
